ENTITY
Cathay Biotech

Cathay Biotech (688065 CH)

50
Analysis
Materials • China
Cathay Biotech Inc. engages in synthetic biology, producing new materials on an industrial scale through bio-manufacturing. The Company focuses on polyamide industry's value chain covering biological long-chain dibasic acid, bio-based pentane diamine, bio-based polyamide, and more. Cathay Biotech markets its products worldwide.
more
•06 May 2024 06:10

CSI300 Index Rebalance Preview: Bounce in the Potential Deletes Could Be Short Lived

There could be 11 changes for the CSI300 in June with multiple days of ADV to trade on most names. The potential deletes have bounced recently but...

Logo
1k Views
Share

CSI300 Index Rebalance Preview: Potential Adds Outperforming Despite ETF Inflows

The adds have outperformed the deleted by over 10% in the last month. Coming up to the end of the review period, there could be further positioning.

Logo
1.3k Views
Share
bullish•ZOZO Inc
•10 Mar 2024 05:50

Index Rebalance & ETF Flow Recap: NKY, ASX, CSI300, A50, STTF, LowVol30, Value Up

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
1.1k Views
Share
•08 Feb 2024 10:02

China ETF Inflows & Impact: Concentrated, Then Diversified; Central Huijin Steps Up

Nearly US$37bn has flowed into mainland China listed ETFs since 2 January and could be driven by the National Team supporting the market. Central...

Logo
769 Views
Share
•28 Jan 2024 05:30

Index Rebalance & ETF Flow Recap: CSI300, CSI500, SSE50, ChiNext, KOSPI200, Renesas, IDX30/LQ45

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
760 Views
Share
x